Bionime Corp Cash Flow Conversion Efficiency
Bionime Corp cash flow conversion efficiency. Based on the latest financial reports, Bionime Corp (4737) has a cash flow conversion efficiency ratio of 0.005x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$9.99 Million ≈ $314.71K USD) by net assets (NT$2.21 Billion ≈ $69.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bionime Corp (2009–2025)
Cash flow conversion efficiency of Bionime Corp from 2009 to 2025. This chart illustrates how Bionime Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bionime Corp stock quote for real-time trading data and today's change.
Bionime Corp Cash Flow Conversion Ratio Explained
Bionime Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bionime Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bionime Corp ranked by their cash flow conversion efficiency. Also see Bionime Corp (4737) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pro-Dex Inc
NASDAQ:PDEX
|
0.086x |
|
Dividend 15 Split Corp II
TO:DF
|
-0.012x |
|
UmweltBank AG
XETRA:UBK
|
-0.132x |
|
DCX Systems Limited
NSE:DCXINDIA
|
0.002x |
|
Unisys Corporation
NYSE:UIS
|
-0.133x |
|
Michman Basad Ltd
TA:MCMN
|
-0.271x |
|
Theta Gold Mines Ltd
AU:TGM
|
-0.181x |
|
Phuoc Hoa Rubber JSC
VN:PHR
|
0.033x |
Annual Cash Flow Conversion Efficiency for Bionime Corp (2009–2025)
The table below shows the annual cash flow conversion efficiency of Bionime Corp from 2009 to 2025. Review Bionime Corp (4737) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.76 Billion ≈ $55.31 Million |
NT$494.80 Million ≈ $15.59 Million |
0.282x | +2626.07% |
| 2024-12-31 | NT$1.89 Billion ≈ $59.51 Million |
NT$19.53 Million ≈ $615.30K |
0.010x | -89.87% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.80 Million |
NT$203.44 Million ≈ $6.41 Million |
0.102x | +49.24% |
| 2022-12-31 | NT$2.08 Billion ≈ $65.55 Million |
NT$142.29 Million ≈ $4.48 Million |
0.068x | -47.36% |
| 2021-12-31 | NT$2.08 Billion ≈ $65.41 Million |
NT$269.72 Million ≈ $8.50 Million |
0.130x | +23.66% |
| 2020-12-31 | NT$2.07 Billion ≈ $65.24 Million |
NT$217.56 Million ≈ $6.85 Million |
0.105x | -46.98% |
| 2019-12-31 | NT$2.05 Billion ≈ $64.49 Million |
NT$405.56 Million ≈ $12.78 Million |
0.198x | +223.97% |
| 2018-12-31 | NT$1.99 Billion ≈ $62.79 Million |
NT$121.90 Million ≈ $3.84 Million |
0.061x | +329.29% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.46 Million |
NT$29.60 Million ≈ $932.53K |
0.014x | -91.95% |
| 2016-12-31 | NT$2.59 Billion ≈ $81.50 Million |
NT$457.84 Million ≈ $14.42 Million |
0.177x | +124.53% |
| 2015-12-31 | NT$2.54 Billion ≈ $80.08 Million |
NT$200.37 Million ≈ $6.31 Million |
0.079x | -70.49% |
| 2014-12-31 | NT$1.35 Billion ≈ $42.44 Million |
NT$359.84 Million ≈ $11.34 Million |
0.267x | +121.73% |
| 2013-12-31 | NT$1.07 Billion ≈ $33.73 Million |
NT$128.98 Million ≈ $4.06 Million |
0.120x | +411.49% |
| 2012-12-31 | NT$1.00 Billion ≈ $31.54 Million |
NT$23.57 Million ≈ $742.74K |
0.024x | -88.22% |
| 2011-12-31 | NT$1.09 Billion ≈ $34.19 Million |
NT$216.93 Million ≈ $6.83 Million |
0.200x | +1387.47% |
| 2010-12-31 | NT$1.02 Billion ≈ $32.02 Million |
NT$13.66 Million ≈ $430.40K |
0.013x | -95.85% |
| 2009-12-31 | NT$640.89 Million ≈ $20.19 Million |
NT$207.56 Million ≈ $6.54 Million |
0.324x | -- |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTE… Read more